Dexcom (DXCM) Stock
Continuous glucose monitoring systems provider for diabetes. Here's the price, business snapshot, and what's worth knowing about Dexcom in October 2026.
DexCom, Inc. (DXCM) designs and sells continuous glucose monitoring (CGM) systems used by people with diabetes and healthcare providers. Its product suite—sensors, transmitters and supporting software—aims to provide real‑time glucose readings and trend data, with recurring revenue from consumable sensors and subscription services. Key positives include strong adoption in type 1 diabetes, a growing addressable market among type 2 patients, ongoing product upgrades (including smaller form factors) and partnerships with insulin‑delivery firms. Risks include competitive pressure (from established medical device makers and newer entrants), reimbursement and regulatory outcomes across markets, supply chain constraints and the potential for device recalls or pricing pressure. With a market capitalisation around $27.4bn, DexCom is often viewed as a growth‑oriented medical device company; investors should weigh revenue visibility from consumables against execution and regulatory risks. This is general information only, not personalised investment advice; returns are not guaranteed and share values can fall as well as rise.
Why It’s Moving
Dexcom Targets Type 2 Diabetes Expansion with New Global Report and Strategic Partnership
- Released the 'State of Type 2 Report' ahead of EASD 2026, identifying low awareness and reimbursement hurdles as key drivers for future CGM adoption in Type 2 care.
- Announced a new partnership to become the official continuous glucose monitor provider for Team Novo Nordisk, enhancing brand visibility in the professional cycling community.
- Analysts note that rising GLP-1 medication use creates a complementary opportunity for Dexcom to expand its addressable market beyond traditional insulin-dependent patients.
Dexcom Targets Type 2 Diabetes Expansion with New Global Report and Strategic Partnership
- Released the 'State of Type 2 Report' ahead of EASD 2026, identifying low awareness and reimbursement hurdles as key drivers for future CGM adoption in Type 2 care.
- Announced a new partnership to become the official continuous glucose monitor provider for Team Novo Nordisk, enhancing brand visibility in the professional cycling community.
- Analysts note that rising GLP-1 medication use creates a complementary opportunity for Dexcom to expand its addressable market beyond traditional insulin-dependent patients.
Sixth Month Growth Performance
When is the next earnings date for DEXCOM INC (DXCM)?
No confirmed upcoming earnings date has been announced for DXCM as of today. Based on the company's historical reporting pattern, which typically follows a quarterly cadence with reports released after market close, the next earnings report is expected in late October 2026. This anticipated release will cover the third quarter of fiscal year 2026. Investors should monitor official corporate communications for the precise scheduling of this event.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying DEXCOM's stock with a target price of $115.51, indicating good growth potential.
Financial Health
Dexcom is generating strong revenue and cash flow, with solid profit margins supporting its growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring revenue growth
Consumable sensors and subscription services support revenue predictability, though sales can fluctuate with reimbursement and competitive dynamics.
Product innovation pipeline
Smaller sensors, improved accuracy and system integrations keep the product roadmap active, but technical or regulatory setbacks can affect adoption.
Global expansion potential
International markets present sizeable opportunity as CGM adoption rises, balanced by differing regulatory regimes and payer systems that can slow rollout.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
